UBS Group
ELAB icon

UBS Group’s Elevai Labs ELAB Stock Holding History

UBS Group’s Portfolio ELAB Stock Details ELAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85K Buy
235
+105
+81% +$2.66K ﹤0.01% 9279
2026
Q1 		$7.8K Buy
130
+123
+1,757% +$15.8K ﹤0.01% 8550
2025
Q4 		$2.51K Buy
+7
New +$8.31K ﹤0.01% 9293
2025
Q3 		– Sell
-3
Closed -$4.81K – 9597
2025
Q2 		$6.07K Buy
3
+1
+50% +$2.16K ﹤0.01% 9117
2025
Q1 		$7.07K Hold
2
– – ﹤0.01% 8858
2024
Q4 		$20.9K Buy
+2
New +$104K ﹤0.01% 7841
2024
Q3 		– Hold
0
– -$4.62K – 9624
2024
Q2 		– Hold
0
– – – 8070
2024
Q1 		– Hold
0
– – – 8317

Other funds holding ELAB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's ELAB Position: Q2 2026 in Review

UBS Group increased its Elevai Labs (ELAB) stake by 81% in Q2 2026, buying an estimated $2.66K and bringing the position to 235 shares worth $2.85K. The position accounts for ﹤0.01% of the portfolio, ranked #9279.

UBS Group first reported a position in ELAB in Q4 2024 and has held it in 6 quarters since. The position peaked at $20.9K in Q4 2024. 11 funds tracked by Wall St. Rank hold ELAB as of Q2 2026.

  • UBS Group held 235 shares of Elevai Labs worth $2.85K as of Q2 2026.
  • UBS Group bought 105 Elevai Labs shares in Q2 2026, an estimated $2.66K.
  • Elevai Labs made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9279 holding.
  • UBS Group first reported a position in Elevai Labs in Q4 2024 and has held it in 6 quarters since.
  • UBS Group's Elevai Labs position peaked at $20.9K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Elevai Labs as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.